¿ Epimmune Inc., of San Diego received a $2 million milestone payment from G.D. Searle & Co., of Skokie, Ill., as a result of Searle¿s accepting a lead product candidate for breast, lung and colon cancers. Searle will conduct clinical trials in the first half of next year.
¿ Micrologix Biotech Inc., of Vancouver, British Columbia, closed on its C$15 million (US$10.1 million) bought-deal financing. The funding will allow the company to start a Phase II trial of MBI 226 for the prevention of central venous catheter-related bloodstream infections as well as start two Phase I trials next year. (See BioWorld Today, Aug. 20, 1999, p. 1.)
¿ Vivus Inc., of Mountain View, Calif., said it received the necessary license to launch Muse (alprostadil) in Spain for the treatment of sexual dysfunction and urologic disorders in men and women. The action prompted a $2 million milestone payment from one of Vivus¿ international partners, AstraZeneca Group plc, of London.